American researchers have developed an experimental “super vaccine” that demonstrated up to 88 percent effectiveness in preventing several aggressive cancers, including pancreatic, breast and skin cancers, in early animal trials.
The breakthrough, led by scientists at the University of Massachusetts Amherst, was detailed in Cell Reports Medicine and could pave the way for next-generation immunotherapies targeting multiple cancer types simultaneously.
Unlike traditional vaccines that trigger a single immune response, the new formulation combines cancer-specific antigens with dual adjuvants inside nanoparticles, activating both the innate and adaptive immune systems for a stronger and longer-lasting defense.
“By designing these nanoparticles to trigger multi-pathway immune activation, we achieved remarkable tumor prevention and survival rates,” said Professor Prabhani Atukorale, co-author of the study.
In trials on mice, 88 percent of subjects exposed to pancreatic cancer, 75 percent to breast cancer, and 69 percent to melanoma remained healthy, with no metastatic spread observed. “Metastasis remains the biggest obstacle in cancer treatment,” Atukorale noted.
Although still in preclinical stages, the findings suggest a potential new frontier in oncology. “This opens a future where personalized cancer vaccines could complement existing treatments to prevent recurrence,” said Aliasger K. Salem, another co-author.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.